Advancements in Multiple Myeloma Treatment: Frontline Approaches and Therapies for Early Relapse : Episode 5
Initial Impressions of the CEPHEUS Clinical Trial in Transplant Not-Preferred NDMM
Panelists discuss how the CEPHEUS trial’s demonstration of improved progression-free survival with daratumumab-VRd versus VRd alone in transplant not-preferred NDMM provides compelling evidence for quadruplet therapy in this setting, though considerations of cost, toxicity management, and patient selection remain important factors in implementation.
Video content above is prompted by the following:
- What are your impressions of the CEPHEUS data that was recently presented?
- How might this impact your clinical practice?
Recent Videos
Related Content
